Veradermics climbs, then eases after upsized $414 mln equity offering

Jefferies Financial

30/04/2026 15:33

** Shares of dermatologist-founded biopharma Veradermics MANE.N down 3.6% at $102.74 on Thurs after increased follow-on priced

** MANE shares rose as much as 7.5% in early trading to $114.50, highest since co went public in Feb IPO at $17

** New Haven, Connecticut-based firm late Weds announced offering ~3.8 mln shares at $100 for gross proceeds of about $384.4 mln

** It also sold pre-funded warrants to buy 300,000 shares for about $30 mln in private placement to entities affiliated with Suvretta Capital

** MANE shares soared nearly 48% to close at $100.10 on Mon after co early that day reported positive late-stage trial results for its male pattern hair loss oral drug

** Co said the extended-release version of minoxidil showed no serious heart-related safety issues, and that it plans further studies, including in women

** Late Mon, co started offering of 3.35 mln shares/pre-funded warrants for broad range of purposes, including commercial launch activities, developing commercialization infrastructure, expanding manufacturing capabilities and R&D, per the prospectus

** Prior to the offering, hedge fund Suvretta owned ~4.2 mln shares of MANE's ~37.3 mln shares outstanding

** Jefferies, Leerink, Citigroup and Cantor joint bookrunners for offering

** All 4 analysts covering the stock are bullish including 1 "strong buy" rating; median PT $111, according to LSEG data

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@tr.com 1-646-279-6380))